Rep. Julie Johnson Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Representative Julie Johnson (D-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Abbott Laboratories Stock Down 1.4%

Shares of NYSE ABT opened at $121.82 on Friday. The firm’s 50 day moving average price is $126.01 and its 200 day moving average price is $128.95. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The firm has a market cap of $211.83 billion, a P/E ratio of 15.27, a price-to-earnings-growth ratio of 2.02 and a beta of 0.72. Abbott Laboratories has a 1 year low of $113.39 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.30. The business had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business’s revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.21 earnings per share. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.1%. Abbott Laboratories’s payout ratio is currently 31.58%.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the business. Sharp Wealth Advisory LLC acquired a new position in Abbott Laboratories in the fourth quarter worth about $227,000. Hopwood Financial Services Inc. lifted its stake in Abbott Laboratories by 6.9% during the fourth quarter. Hopwood Financial Services Inc. now owns 3,170 shares of the healthcare product maker’s stock worth $397,000 after purchasing an additional 204 shares during the last quarter. Genesee Capital Advisors LLC boosted its holdings in Abbott Laboratories by 7.8% in the fourth quarter. Genesee Capital Advisors LLC now owns 9,273 shares of the healthcare product maker’s stock worth $1,162,000 after purchasing an additional 669 shares during the period. BridgePort Financial Solutions LLC increased its stake in Abbott Laboratories by 3.7% during the fourth quarter. BridgePort Financial Solutions LLC now owns 2,591 shares of the healthcare product maker’s stock valued at $325,000 after purchasing an additional 92 shares during the last quarter. Finally, Aberdeen Group plc lifted its holdings in Abbott Laboratories by 1.2% in the fourth quarter. Aberdeen Group plc now owns 1,993,536 shares of the healthcare product maker’s stock worth $249,770,000 after acquiring an additional 23,817 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on ABT. Raymond James Financial increased their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Benchmark started coverage on Abbott Laboratories in a research report on Friday, October 10th. They issued a “buy” rating and a $145.00 target price on the stock. The Goldman Sachs Group cut their price target on shares of Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Daiwa Capital Markets boosted their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Finally, Barclays raised their target price on shares of Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $147.42.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.